|Bid||73.30 x 3100|
|Ask||73.75 x 1100|
|Day's range||72.23 - 74.05|
|52-week range||56.26 - 83.85|
|Beta (3Y monthly)||0.37|
|PE ratio (TTM)||31.55|
|Earnings date||30 Apr 2019|
|Forward dividend & yield||2.20 (2.65%)|
|1y target est||87.36|
Although sales of Clovis' (CLVS) Rubraca improved in the fourth quarter of 2018, the drug may face significant competition going forward. Clovis is also evaluating Rubrca for other cancer indications.
With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.
Share price of Novo Nordisk (NVO) has increased year to date on strong presence in the Diabetes Care market and a solid pipeline.
Plunging healthcare stocks dragged Wall Street lower on Wednesday, offsetting a spate of upbeat corporate earnings and encouraging economic data from the United States and China. All three major U.S. stock indexes were down, but the S&P 500 slipped to more than a percent below its record high reached in September.
U.S. stocks headed lower on Wednesday, as a selloff in healthcare stocks extended for a second day, overshadowing a rally in chipmakers led by Qualcomm. Medical device maker Abbott Laboratories Inc fell 3.8%, despite quarterly results beating estimates. UnitedHealth Group Inc, Pfizer Inc and Merck & Co fell more than 2% and were the biggest drags on the broader S&P 500 index.
Gilead (GILD) collaborates with data-driven company, Insitro, to harness the power of computers to discover and develop therapies for treating NASH (fatty liver).
J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2019 and raises 2019 guidance for operational sales and adjusted operational EPS growth. Shares up in pre-market trading.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months
Merck (MRK), known as MSD outside the United States and Canada, today announced the first presentation of results from ASPECT-NP, a randomized, double-blind, multi-center Phase 3 clinical trial evaluating the efficacy and safety of ZERBAXA® (ceftolozane and tazobactam) for the treatment of adult patients with ventilated nosocomial (hospital acquired) pneumonia. The results demonstrated non-inferiority of an investigational dose of ZERBAXA to meropenem, the active comparator, in the primary and key secondary endpoints.
Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
Germany's Merck KGaA sealed a $6.5 billion (4.9 billion pounds) takeover deal with Versum Materials after overturning a deal it had agreed with rival bidder Entegris. A bet on a recovery in electronic materials markets for semiconductor makers, the transaction will boost the share of profit that diversified Merck derives from high-tech chemicals to 27 percent from 19 percent previously. Merck, also maker of pharmaceuticals and biotech production gear, this week won the backing of Versum's board for its $53-per-share offer, lifted from $48 previously, having been spurned for weeks.
KEYTRUDA Now Approved for First-Line Treatment of Patients with Stage III NSCLC Who Are Not Candidates for Surgical Resection or Definitive Chemoradiation, or Metastatic NSCLC, and
The S&P financial index rose 0.54%, while the banking sector was up 0.36%. Earnings of S&P 500 bank are expected to grow 1.8% in the first quarter, well below 8.2% estimated six months ago, according to Refinitiv data. The steep drop in the estimate comes in the wake of the Federal Reserve's dovish tilt and the subsequent drop in 10-year Treasury yields.
Intercept Pharmaceuticals (ICPT) reports positive additional supportive data from its phase III REGENERATE study of obeticholic acid in patients with liver fibrosis due to NASH.
Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.
AstraZeneca (AZN) and Merck gain an EU approval for Lynparza as a monotherapy for treating HER2-negative locally-advanced/metastatic breast cancer.